Current issues in resynchronization therapy of patients with heart failure

1. Hawkins NM, Petrie MC, MacDonald MR et al. Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony? Eur Heart J 2006; 27: 1270–1281.

2. Vernooy K, Verbeek XAAM, Peschar M et al. Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J 2005; 26: 91–98.

3. Spragg DD, Leclercq C, Loghmani M et al. Regional alterations in protein expression in the dyssynchronous failing heart. Circulation 2003; 108: 929–932.

4. Nowak B, Sinha AM, Schaefer WM et al. Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2003; 41: 1523–1528.

5. Ukkonenen H, Beanlands RS, Burwash IG et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation 2003; 107: 28–31.

6. Sundell J, Engblom E, Koistinen J et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2004; 43: 1027–1033.

7. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873–880.

8. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–1853.

9. Auricchio A, Stellbrink C, Sack S et al. Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long‑term clinical effect of haemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026–2033.

10. Auricchio A, Stellbrink C, Butter C et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol 2003; 42: 2109–2116.

11. Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454–1459.

12. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioverter defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003; 289: 2685–2694.

13. Abraham WT, Young JB, León AR et al. Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004; 110: 2864–2868.

14. Bristow MR, Saxon LA, Boehmer J et al. Comparison of Medical Therapy, Pacing, Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–2150.

15. Cleland JGF, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. The CArdiac REsynchronization-Heart Failure (CARE-HF) Study Investigators. N Engl J Med 2005; 352: 1539–1549.

16. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure: a meta‑analysis of randomized controlled trials. JAMA 2003; 289: 730–740.

17. Mc Alister FA, Ezekowitz JA, Wiebe N et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 381–390.

18. Freemantle N, Tharmanathan P, Calvert MJ et al. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction: a systematic review and meta‑analysis. Eur J Heart Fail 2006; 8: 433–440.

19. Linde C, Leclercq C, Rex S et al. Long‑term benefits of biventricular pacing in congestive heart failure: results from the MUSTIC study. J Am Coll Cardiol 2002; 40: 111–118.

20. Cleland JGF, Daubert JC, Erdmann E et al. Longer‑term effects of cardiac resynchronisation therapy on mortality in heart failure [The Cardiac Resynchronisation-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928–1932.

21. Duncan A, Wait D, Gibson D et al. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left biventricular systolic dysfunction and activation disturbances in sinus rhythm: sub‑study of the MUSTIC trial. Eur Heart J 2003; 24: 430–441.

22. Stellbrink C, Breithardt OA, Franke A. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol 2001; 38: 1957–1965.

23. St John Sutton MG, Plappert T, Abraham WT et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107: 1985–1990.

24. Leclercq C, Hare JM. Ventricular resynchronization. Current state of the art. Circulation 2004; 109: 296–299.

25. Bleeker GB, Schalij MJ, Molhoek SG et al. Frequency of left ventricular dyssynchrony in patients with heart failure and a narrow QRS complex. Am J Cardiol 2005; 95: 140–142.

26. Ghio S, Constantin C, Klersy C et al. Interventricular and intraventricular dysynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J 2004; 25: 571–578.

27. Bader H, Garrigue S, Lafitte S et al. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol 2004; 43: 248–256.

28. Yu CM, Chan YS, Zhang Q et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol 2006; 48: 2251–2257.

29. Achilli A, Sassara M, Ficili S et al. Long‑term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and narrow QRS. J Am Coll Cardiol 2003; 42: 2117–2124.

30. Gasparini M, Mantica M, Galimberti P et al. Beneficial effects of biventricular pacing in patients with a narrow QRS. Pacing Clin Electrophysiol 2003; 26: 169–174.

31. Bleeker GB, Holman ER, Steendijk P et al. Cardiac resynchronisation therapy in patients with a narrow QRS complex. J Am Coll Cardiol 2006; 48: 2243–2250.

32. Daubert JC. Atrial fibrillation and heart failure: a mutually noxious association. Europace 2004; 5: S1–S4.

33. Baldasseroni S, Opasich C, Gorini M et al. Left bundle branch block is associated with increased 1-year sudden and total mortality rate in 5,517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143: 398–405.

34. Leclercq C, Walker S, Linde C et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780–1787.

35. Gasparini M, Auricchio A, Regoli F et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006; 48: 734–743.

36. Wilkoff BL, Cook JR, Epstein AE et al. Dual-chamber or ventricular backup pacing in patients with an implantable defibrillator: the dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288: 3115–3123.

37. Sweeney MO, Hellkamp AS, Ellenbogen KA et al. Adverse effect of ventricular pacing in heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107: 2932–2937.

38. Leclercq C, Cazeau S, Lellouche D et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF study. Pacing Clin Electrophysiol 2007; 30: S23–S30.

39. Fantoni C, Kawabata M, Massaro R et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non‑fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol 2005; 16: 112–120.

40. Linde C, Abraham WT, Gold MR et al. Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. J Am Coll Cardiol 2008; 52: 1834–1843.

41. Epstein EA, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 Guidelines for device‑based therapy of cardiac rhythm abnormalities: Executive summary. J Am Coll Cardiol 2008; 51: 2085–2105.

42. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2006; 114: e385–e484.

43. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl Med 1996; 335: 1933–1940.

44. Buxton AE, Lee KL, Fisher JD et al for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882–1890.

45. Moss AJ, Zareba W, Hall JW et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.

46. Bardy GH, Lee KL, Mark DB et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.

47. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151–2158.

48. Strickberger SA, Hummel JD, Bartlett TG et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with non‑ischemic dilated cardiomyopathy and asymptomatic non‑sustained ventricular tachycardia – AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707–1712.

49. Bänsch D, Antz M, Boczor S et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453–1458.

50. Auricchio A, Metra M, Gasparini M et al for the Multicenter Longitudinal Observational Study (MILOS) Group. Long‑term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol 2007; 99: 232–238.

51. Yao G, Freemantle N, Calvert MJ et al. The long‑term cost‑effectiveness of cardiac resynchronisation therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28: 42–51.